|Mr. John C. Poss||Chairman, CEO & Pres||341.03k||N/A||1948|
|Ms. Ksenia Griswold||COO, CFO, VP & Controller||226.15k||N/A||1983|
|Dr. Andrea Small-Howard M.B.A., Ph.D., MBA||Chief Science Officer & Director||135.38k||N/A||1969|
|Mr. Krin Ellery Kuethe||Sr. VP of Cultivation||471.18k||N/A||1984|
|Mr. John B. Davis||Gen. Counsel & Exec. VP||N/A||N/A||N/A|
GB Sciences, Inc. focuses to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for various ailments. The company is developing technologies in plant biology, cultivation and extraction techniques, which are combined with biotechnology; and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. GB Sciences, Inc. has an agreement with Growblox Sciences, Puerto Rico, LLC that grants the right to its technology and intellectual property. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
GB Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.